Join

Compare · ABCM vs BIO

ABCM vs BIO

Side-by-side comparison of Abcam plc (ABCM) and Bio-Rad Laboratories Inc. (BIO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • ABCM operates in Health Care, while BIO operates in Industrials - the two are in different parts of the market.
  • BIO is the larger of the two at $6.92B, about 1.5x ABCM ($4.59B).
  • BIO has hit the wire 3 times in the past 4 weeks while ABCM has been quiet.
  • BIO has more recent analyst coverage (11 ratings vs 3 for ABCM).
MetricABCMBIO
Company
Abcam plc
Bio-Rad Laboratories Inc.
Price
$23.98+0.00%
$256.19-8.55%
Market cap
$4.59B
$6.92B
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Laboratory Analytical Instruments
Exchange
NASDAQ
NYSE
IPO
2020
1980
News (4w)
0
3
Recent ratings
3
11
ABCM

Abcam plc

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

BIO

Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.